IEAtlas

IEAtlas catalogs HLA-presented immune epitopes derived from non-coding regions to support research into cancer immunotherapies.

Key Features:

• Comprehensive Epitope Database: Identifies and catalogs 245,870 non-canonical epitopes that bind HLA-I/II allotypes across 15 cancer types and 30 non-cancerous tissues.
• Reanalysis of Mass Spectrometry Datasets: Reanalyzes publicly available mass spectrometry-based HLA immunopeptidome datasets integrated with benchmarked non-canonical open reading frame information.
• Immunogenicity Evaluation: Evaluates immunogenic potential using features including HLA binding affinity, stability, and T-cell receptor recognition.
• Biochemical Properties and Clinical Relevance: Provides biochemical property annotations for each epitope and clinical relevance of corresponding genes across major cancer types and normal tissues.
• Flexible Analysis Tools: Supplies analysis functions for retrieval and interrogation of epitopes derived from non-coding regions.

Scientific Applications:

• Immunogenicity Assessment: Serves as a resource for investigating the immunogenic capacity of non-canonical epitopes.
• Therapeutic Cancer Vaccine Discovery: Supports research into potential therapeutic cancer vaccines by prioritizing non-canonical epitopes that can engage the immune system against tumor cells.
• Cancer Immunotherapy Research: Provides comprehensive datasets and analytical outputs to advance basic and applied cancer immunotherapy research.

Methodology:

IEAtlas reanalyzes publicly available mass spectrometry-based HLA immunopeptidome datasets and integrates them with benchmarked non-canonical open reading frame information to identify and catalog epitopes, and evaluates immunogenic potential using features including HLA binding affinity, stability, and T-cell receptor recognition.